These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31278627)

  • 21. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
    Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
    Hassaballa HA; Lateef OB; Silver MR; Balk RA
    J Crit Care; 2005 Mar; 20(1):111-3. PubMed ID: 16015525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of immunological changes following realgar and arsenic trioxide treatments in a murine model of myelodysplastic syndrome.
    Tao Y; Xue T; Li X; Guo R; Wang Y; Xu H; Hu K; Dong X; Wang D; Ren J; Guan Y; Lu J
    Immunopharmacol Immunotoxicol; 2024 Jun; 46(3):408-416. PubMed ID: 38816179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
    Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
    Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Safety evaluation of niuhuang jiedu tablet].
    Feng YL; Miao JW; Li J; Sung AS; Liu J
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3221-5. PubMed ID: 25522601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
    Zheng WL; Zhang GS; Xu YX; Shen JK; Dai CW; Pei MF
    Leuk Res; 2008 Feb; 32(2):251-4. PubMed ID: 17920679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Realgar (α-As
    Zhang M; Zhang JY; Sun MQ; Lu P; Liu JX
    Chin J Integr Med; 2022 Mar; 28(3):281-288. PubMed ID: 32418175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Karyotype and DNA-Methylation Responses in Myelodysplastic Syndromes following Treatment with Traditional Chinese Formula Containing Arsenic.
    Shuzhen S; Rou M; Xiaomei H; Xiao-Hong Y; Yong-Gang X; Hongzhi W; Xiu-Peng Y
    Evid Based Complement Alternat Med; 2012; 2012():969476. PubMed ID: 23118798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
    Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
    J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro.
    Xu M; Ren JY; Guo YC; Xu BX; Zeng Q; Hu Q; Zhou YM; Lu JH
    Leuk Res; 2017 Nov; 62():4-11. PubMed ID: 28963909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
    Ofran Y; Avivi I; Gesundheit B; Or R; Rowe JM; Zuckerman T
    Am J Hematol; 2007 Apr; 82(4):332-3. PubMed ID: 17080434
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of the traditional Chinese medicine compound Yisui Lixue decoction on apoptosis of marrow cells in rats with myelodysplastic syndrome induced by 
dimethyl benzanthracene].
    Huang Y; Xiong D; Xu Y; Yu J; Xian Y; Cai E
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 42(1):26-34. PubMed ID: 28216494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxic epidermal necrolysis after extensive dermal use of realgar-containing (arsenic sulfide) herbal ointment.
    Wu ML; Deng JF
    Clin Toxicol (Phila); 2013; 51(8):801-3. PubMed ID: 24003889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of TCM syndrome-typing based therapy combined with cyclosporin in treating myelodysplastic syndrome].
    Liu L; Shu X; Hu NP
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Oct; 26(10):933-5. PubMed ID: 17121049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
    J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of L-Leucine Therapy on Hematopoietic Function in Elderly Myelodysplastic Syndrome Patients.
    Ito K; Hayashi T; Inaguma Y; Terazawa T; Ando M; Ando Y; Tsuge M; Kato A; Shimato A; Suzuki S; Kato S; Tomita A; Yamada S; Emi N
    Biol Pharm Bull; 2019 Oct; 42(10):1651-1657. PubMed ID: 31341143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.